Clinical Trials and the Clinical Pharmacologist
نویسندگان
چکیده
منابع مشابه
The clinical pharmacologist.
THE controversy over prescribing drugs by their trade or approved names is a source of embarrassment to teachers of therapeutics like myselfwho have, for many years, taught medical students and young doctors to prescribe by approved names, leaving the choice of preparation to the pharmacist, on the assumption that 'the drug is the same'. Today we have to eat our words and recognize, in Sir Phil...
متن کاملEvaluation of Clinical Trials
In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...
متن کاملEvidence Based Medicine: Clinical Trials
Evidence based medicine is very important for success of modern medicine. It is the ongoing process of using the most reliable evidence from clinical studies, scientific understanding and medical practice to make the best possible medical choice for patients. Evidence based medicine is how medicine advances and how we get improvements in life expectancy and quality of life. It not only identifi...
متن کاملRole of clinical pharmacologist in detection and prevention of administration errors: an observational and interventional study
Abstract The aim of this study was to describe and evaluate the prevention of drug administration errors by clinical pharmacologist interventions in patients with cancer. This observational study was performed in the hematology-oncology ward of an academic hospital. The clinical pharmacologist in coordination with the professors of the ward reviewed patients’ medical records and monitored pat...
متن کاملClinical pharmacy and clinical trials
CPC-148 Table 1 adalimumab infliximab ustekinumab Lost to follow-up 5% (1/20) 23.5% (4/17) 22% (2/9) Continuing treatment 40% (8/20) 29.4% (5/17) 67% (6/9) Withdrawal/ Discontinuation by doctor 5% (1/20) 5.9% (1/17) 11% (1/9) Discontinuation due to good response 20% (4/20) – – Change of treatment 30% (6/20) 41.2% (7/17) – The causes of the discontinuation/change of treatment were: Abstract CPC-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
سال: 1979
ISSN: 1882-8272,0388-1601
DOI: 10.3999/jscpt.10.641